Jasper Therapeutics Inc. (JSPR)
| Bid | 4.53 |
| Market Cap | 68.51M |
| Revenue (ttm) | 1.17M |
| Net Income (ttm) | 0 |
| EPS (ttm) | -4.89 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | -0.93 |
| Analyst | Buy |
| Ask | 4.73 |
| Volume | 264,039 |
| Avg. Volume (20D) | 306,703 |
| Open | 4.51 |
| Previous Close | 4.37 |
| Day's Range | 4.56 - 4.90 |
| 52-Week Range | 3.13 - 26.84 |
| Beta | 2.56 |
About JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The co...
Analyst Forecast
According to 9 analyst ratings, the average rating for JSPR stock is "Buy." The 12-month stock price forecast is $64, which is an increase of 1303.42% from the latest price.
Stock Forecasts
5 months ago · seekingalpha.com
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And AsthmaJasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved...